Summit, Akeso’s China approval celebration cut short as survival benefit degrades
Latest BioSpace coverage of Summit, Akeso’s China approval celebration cut short as survival benefit degrade
Summit Therapeutics
Summit Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of innovative therapies for serious unmet medical needs, with a leading oncology asset ivonescimab (a PD-1/VEGF bispecific antibody) in-licensed from Akeso for global development.
Company Info
Sector:Biopharmaceuticals / Oncology
Headquarters:Miami, Florida, USA (research operations in Cambridge, UK)
Founded:2003
Website:www.smmttx.com/
Upcoming Milestones & Key Dates
Q3 2026
Regulatory
FDA decision on ivonescimab BLA for 1L NSCLC
Q4 2026
Clinical Trial
HARMONi-3 confirmatory trial interim readout
Clinical Development Pipeline
Ivonescimab (AK112/SMT112)
Target: PD-1/VEGF bispecific antibodyIvonescimab
Target: PD-1/VEGF bispecific antibodySMT-001
Target: Disclosed in 2026 R&D updateRecent News
Summit and Akeso's PD-1xVEGF bispecific got a new approval in China. It came with an unwelcome surprise
Endpoints News reports Summit Therapeutics and Akeso's PD-1xVEGF bispecific ivonescimab won a new approval in China, but longer-follow-up data showed a smaller survival benefit than expected.
Summit, Merck must navigate new regulatory terrain in China-first cancer landscape
Summit, Merck must navigate new regulatory terrain in China-first cancer landscape.
Summit counters PD-1/VEGF skeptics; Celldex drug fails skin disease study
Summit counters PD-1/VEGF skeptics; Celldex drug fails skin disease study.
Summit has less than a year of cash runway left as PD-1/VEGF verdict nears
Summit has less than a year of cash runway left as PD-1/VEGF verdict nears.
Updated: Summit reports two-year survival data for Western patients, though context lacking
Summit Therapeutics reported two-year survival data for Western patients on ivonescimab, though context was lacking.
Summit updates ivonescimab survival data ahead of PDUFA
In the latest ivonescimab survival data, 'most western patients have now discontinued treatment or completed two years of treatment,' Summit said.
Summit sells failed antibiotic to OpenAI-backed startup
Summit sells failed antibiotic to OpenAI-backed startup
Summit Therapeutics Withdraws $500M Public Offering Due to Market Conditions
Summit Therapeutics announced withdrawal of proposed $500 million public offering effective June 10, 2026, due to unfavorable market conditions.
Summit Therapeutics Withdraws $500M Public Offering Due to Market Conditions
Summit Therapeutics announced withdrawal of proposed $500 million public offering effective June 10, 2026, due to unfavorable market conditions.